Myeloproliferative Neoplasms | Specialty

First-in-Class LSD1 Inhibitor Elicits Clinical Activity in Advanced Myelofibrosis

July 24th 2020

Findings from a phase 2 study presented during the 2020 European Hematology Association Congress shed light on the first-in-class, investigational lysine-specific demethylase-1 inhibitor, bomedemstat, along with its promising clinical activity and tolerable safety profile as monotherapy in patients with advanced myelofibrosis.

MPN Armamentarium Continues to Evolve Amid Expanding Pipeline

July 24th 2020

Ruben A. Mesa, MD, FACP, discussed the current state of treatment in essential thrombocythemia and polycythemia vera, the underutilization of fedratinib in myelofibrosis, and emerging JAK inhibitors on the horizon.

Shammo Previews the Potential of Pevonedistat Combo in High-Risk MDS

July 23rd 2020

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

Genetic Testing Could Lead to Improved Treatment Decisions, Predicted Outcomes in MPNs, MDS

July 23rd 2020

Mutually exclusive gene combinations were observed between specific subtypes of patients with myelodysplastic syndromes and myeloproliferative neoplasms and most other types of MDS/MPNs that have an impact on patient outcomes.

Dr. Mesa on Recent Data With Momelotinib in MPNs and Myelofibrosis

July 17th 2020

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.

Dr. Hoffman on the Safety Profile of PTG-300 in Polycythemia Vera

July 10th 2020

Ronald Hoffman, MD, discusses the safety profile of the first-in-class synthetic hepcidin mimetic agent PTG-300 in patients with polycythemia vera.

Dr. Hoffman on Advantages of Self-Administration With PTG-300 in Polycythemia Vera

July 7th 2020

Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).

FDA Approves Oral Decitabine Plus Cedazuridine for MDS

July 7th 2020

The FDA has approved an oral combination comprised of decitabine and cedazuridine for the treatment of select adult patients with myelodysplastic syndromes.

Advances in the Management of MPNs

July 7th 2020

Essential Thrombocythemia: Treatment Optimization

July 7th 2020

Classifying Patients With Essential Thrombocythemia

July 7th 2020

Primary Myelofibrosis: Trials of Interest

July 7th 2020

JAK2 Inhibitor Selection for Primary Myelofibrosis

July 7th 2020

Fedratinib for Primary Myelofibrosis

July 7th 2020

Ruxolitinib and Surgical Interventions

July 7th 2020

Ruxolitinib for Primary Myelofibrosis

July 7th 2020

Treating Intermediate/High-Risk Primary Myelofibrosis

July 7th 2020

Management of Low-Risk Primary Myelofibrosis

July 7th 2020

Primary Myelofibrosis: Risk Stratification

July 7th 2020

Polycythemia Vera: PROUD-PV Trial

July 7th 2020